Innovent Biologics (HKG:1801) obtained approval for Jaypirca from China's National Medical Products Administration, a Monday bourse filing showed.
The approval is for the drug as monotherapy to treat adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.